{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:26:00Z","timestamp":1790691960850,"version":"4.1.0"},"reference-count":152,"publisher":"Baishideng Publishing Group Inc.","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2019,8,28]]},"DOI":"10.3748\/wjg.v25.i32.4580","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T12:15:18Z","timestamp":1566994518000},"page":"4580-4597","source":"Crossref","is-referenced-by-count":40,"title":["Chronic hepatitis delta: A state-of-the-art review and new therapies"],"prefix":"10.3748","volume":"25","author":[{"given":"Christy","family":"Gilman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Rizzetto M, Canese MG, Aric\u00f2 S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18: 997-1003","DOI":"10.1136\/gut.18.12.997"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980; 141: 590-602","DOI":"10.1093\/infdis\/141.5.590"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Sagnelli E, Felaco FM, Filippini P, Pasquale G, Peinetti P, Buonagurio E, Aprea L, Pulella C, Piccinino F, Giusti G. Influence of HDV infection on clinical, biochemical and histological presentation of HBsAg positive chronic hepatitis. Liver 1989; 9: 229-234","DOI":"10.1111\/j.1600-0676.1989.tb00404.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12217"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.025"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Tamura I, Kurimura O, Koda T, Ichimura H, Katayama S, Kurimura T, Inaba Y. Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan. J Gastroenterol Hepatol 1993; 8: 433-436","DOI":"10.1111\/j.1440-1746.1993.tb01543.x"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46: 420-426","DOI":"10.1136\/gut.46.3.420"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.244.dtv"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20755"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316601"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Radjef N, Gordien E, Ivaniushina V, Gault E, Ana\u00efs P, Drugan T, Trinchet JC, Roulot D, Tamby M, Milinkovitch MC, D\u00e9ny P. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004; 78: 2537-2544","DOI":"10.1128\/JVI.78.5.2537-2544.2004"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3201\/eid1209.060112"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01324.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13604"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1086\/655808"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000795"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2018.03.013"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci USA 1980; 77: 6124-6128","DOI":"10.1073\/pnas.77.10.6124"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.22.8774"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/323558a0"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/323508a0"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Lin JH, Chang MF, Baker SC, Govindarajan S, Lai MM. Characterization of hepatitis delta antigen: specific binding to hepatitis delta virus RNA. J Virol 1990; 64: 4051-4058","DOI":"10.1128\/JVI.64.9.4051-4058.1990"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Bonino F, Hoyer B, Shih JW, Rizzetto M, Purcell RH, Gerin JL. Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun 1984; 43: 1000-1005","DOI":"10.1128\/IAI.43.3.1000-1005.1984"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol 1986; 58: 945-950","DOI":"10.1128\/JVI.58.3.945-950.1986"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.024"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Chang MF, Baker SC, Soe LH, Kamahora T, Keck JG, Makino S, Govindarajan S, Lai MM. Human hepatitis delta antigen is a nuclear phosphoprotein with RNA-binding activity. J Virol 1988; 62: 2403-2410","DOI":"10.1128\/JVI.62.7.2403-2410.1988"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Xia YP, Yeh CT, Ou JH, Lai MM. Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex. J Virol 1992; 66: 914-921","DOI":"10.1128\/JVI.66.2.914-921.1992"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2007.07.034"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Chang MF, Chang SC, Chang CI, Wu K, Kang HY. Nuclear localization signals, but not putative leucine zipper motifs, are essential for nuclear transport of hepatitis delta antigen. J Virol 1992; 66: 6019-6027","DOI":"10.1128\/JVI.66.10.6019-6027.1992"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1017\/s1355838202026432"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02083-09"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2003.10.024"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.23.13325-13334.2004"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.21.10161-10169.2001"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Fu TB, Taylor J. The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates. J Virol 1993; 67: 6965-6972","DOI":"10.1128\/JVI.67.12.6965-6972.1993"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.8.3920-3927.2002"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Modahl LE, Macnaughton TB, Zhu N, Johnson DL, Lai MM. RNA-Dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol Cell Biol 2000; 20: 6030-6039","DOI":"10.1128\/MCB.20.16.6030-6039.2000"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Weiner AJ, Choo QL, Wang KS, Govindarajan S, Redeker AG, Gerin JL, Houghton M. A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol 1988; 62: 594-599","DOI":"10.1128\/JVI.62.2.594-599.1988"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Sharmeen L, Kuo MY, Dinter-Gottlieb G, Taylor J. Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage. J Virol 1988; 62: 2674-2679","DOI":"10.1128\/JVI.62.8.2674-2679.1988"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Casey JL, Gerin JL. Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. J Virol 1995; 69: 7593-7600","DOI":"10.1128\/JVI.69.12.7593-7600.1995"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-73-1-183"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Glenn JS, White JM. trans-dominant inhibition of human hepatitis delta virus genome replication. J Virol 1991; 65: 2357-2361","DOI":"10.1128\/JVI.65.5.2357-2361.1991"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Chao M, Hsieh SY, Taylor J. Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J Virol 1990; 64: 5066-5069","DOI":"10.1128\/JVI.64.10.5066-5069.1990"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M004477200"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Glenn JS, Watson JA, Havel CM, White JM. Identification of a prenylation site in delta virus large antigen. Science 1992; 256: 1331-1333","DOI":"10.1126\/science.1598578"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Ryu WS, Bayer M, Taylor J. Assembly of hepatitis delta virus particles. J Virol 1992; 66: 2310-2315","DOI":"10.1128\/JVI.66.4.2310-2315.1992"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.19.8490"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Lee CZ, Chen PJ, Chen DS. Large hepatitis delta antigen in packaging and replication inhibition: role of the carboxyl-terminal 19 amino acids and amino-terminal sequences. J Virol 1995; 69: 5332-5336","DOI":"10.1128\/JVI.69.9.5332-5336.1995"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Hwang SB, Lai MM. Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen. J Virol 1993; 67: 7659-7662","DOI":"10.1128\/JVI.67.12.7659-7662.1993"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Sureau C, Guerra B, Lanford RE. Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. J Virol 1993; 67: 366-372","DOI":"10.1128\/JVI.67.1.366-372.1993"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1996.0191"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.036"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Saracco G, Rosina F, Brunetto MR, Amoroso P, Caredda F, Farci P, Piantino P, Bonino F, Rizzetto M. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987; 5: 274-281","DOI":"10.1016\/S0168-8278(87)80032-6"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(85)92497-3"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Crax\u00ec A, Raimondo G, Longo G, Giannuoli G, De Pasquale R, Caltagirone M, Patti S, Squadrito G, Pagliaro L. Delta agent infection in acute hepatitis and chronic HBsAg carriers with and without liver disease. Gut 1984; 25: 1288-1290","DOI":"10.1136\/gut.25.11.1288"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Liaw YF, Chen TJ, Chu CM, Lin HH. Acute hepatitis delta virus superinfection in patients with liver cirrhosis. J Hepatol 1990; 10: 41-45","DOI":"10.1016\/0168-8278(90)90071-X"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13834"},{"key":"ref62","unstructured":"Govindarajan S, Fields HA, Humphrey CD, Margolis HS. Pathologic and ultrastructural changes of acute and chronic delta hepatitis in an experimentally infected chimpanzee. Am J Pathol 1986; 122: 315-322"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Colombo P, Di Blasi F, Magrin S, Fabiano C, Di Marco V, D'Amelio L, Lojacono F, Spinelli G, Crax\u00ec A. Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. J Hepatol 1991; 12: 64-69","DOI":"10.1016\/0168-8278(91)90911-T"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(82)90156-8"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Cole SM, Gowans EJ, Macnaughton TB, Hall PD, Burrell CJ. Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen. Hepatology 1991; 13: 845-851","DOI":"10.1002\/hep.1840130508"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02593.x"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.011"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306767"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0012"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14617"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.035"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Krogsgaard K, Kryger P, Aldershvile J, Andersson P, S\u00f8rensen TI, Nielsen JO. Delta-infection and suppression of hepatitis B virus replication in chronic HBsAg carriers. Hepatology 1987; 7: 42-45","DOI":"10.1002\/hep.1840070110"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Buti M, Esteb\u00e1n R, Jardi R, Allende H, Esteb\u00e1n JI, Genesca J, Guardia J. Clinical and serological outcome of acute delta infection. J Hepatol 1987; 5: 59-64","DOI":"10.1016\/S0168-8278(87)80062-4"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Moestrup T, Hansson BG, Widell A, Nordenfelt E. Clinical aspects of delta infection. Br Med J (Clin Res Ed) 1983; 286: 87-90","DOI":"10.1136\/bmj.286.6359.87"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.5.925"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Wu JC, Chen TZ, Huang YS, Yen FS, Ting LT, Sheng WY, Tsay SH, Lee SD. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995; 108: 796-802","DOI":"10.1016\/0016-5085(95)90453-0"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Smedile A, Dentico P, Zanetti A, Sagnelli E, Nordenfelt E, Actis GC, Rizzetto M. Infection with the delta agent in chronic HBsAg carriers. Gastroenterology 1981; 81: 992-997","DOI":"10.1016\/S0016-5085(81)80003-0"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12251"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13205"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13: 1052-1056","DOI":"10.1002\/hep.1840130608"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401133300202"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, Serra G, Lai ME, Loy M, Caruso L, Desmet V, Purcell RH, Balestrieri A. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-1749","DOI":"10.1053\/j.gastro.2004.03.017"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21325"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A, Bonino F, Rizzetto M, Verme G, Craxi A. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14: 154-157","DOI":"10.1111\/j.1600-0676.1994.tb00065.x"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01279.x"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21296"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.5754\/hge10126"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12788"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02542.x"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.09.027"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912696"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27102"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.05.029"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28876"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101002"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.0002"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00096-07"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01902-09"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.3.1613-1622.2005"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26211"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1389"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24758"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.008"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15338-0"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.016"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Wedemeyer H, Bogomolov P, Blank A. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV co-infection. J Hepatol 2018","DOI":"10.1016\/S0168-8278(18)30224-1"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Wedemeyer H, Sch\u00f6neweis K, Bogomolov P. Interim results of a multicentre, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with peg-Interferon alpha 2a in patients with chronic HBV\/HDV co-infection. Hepatology 2018","DOI":"10.1016\/S0618-8278(19)30141-0"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.20.10465-10472.2002"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00074-2"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29658"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Yurdaydin C, ldilman R, Keskin. A phase 2 dose optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study. J Hepatol 2017","DOI":"10.1016\/S0168-8278(17)30327-6"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Koh C, Surana P, Han T, Fryzek N, Kapuria D, Etzion O. A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis - end of study results from the LOWR HDV-3 study. J Hepatol 2017","DOI":"10.1016\/S0168-8278(17)30464-6"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Wedemeyer H, Port K, Deterding K. A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafamib with ritonavir in HDV-4 (LOWR HDV-4) study. J Hepatol 2017","DOI":"10.1016\/S0168-8278(17)30310-0"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1393-1401.2006"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01003-13"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01005-13"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140909"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156667"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30288-1"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Bazinet N, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Vaillant A. Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV\/HDV co-infection: 18 month follow-up results from the REP 301-LTF study. J Hepatol 2018","DOI":"10.1016\/S0168-8278(18)31266-2"},{"key":"ref122","unstructured":"Bazinet M, Pantea V, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, et al. Interim follow-up analysis in the REP 401 protocol: functional control of HBeAg negative chronic HBV infection persists after withdrawal of combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon \u03b1-2a. Hepatology 2018"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1038\/ni875"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23743"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.022"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.363"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.6.3851-3854.2005"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.018"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0812395"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.02.022"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20184"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.07.023"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Etzion O, Hamid S, Yurie L. End of Study Results from LIMT HDV Study: 36% Durable Virologic Response at 24 Weeks Post-Treatment with Pegylated Interferon Lambda Monotherapy in Patients with Chronic hepatitis Delta Virus Infection. J Hepatology 2019; 70: e32","DOI":"10.1016\/S0618-8278(19)30058-1"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.12.022"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2017.05.002"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13081"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02012-08"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-016-0514-6"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02297-13"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.10.002"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"Nakasone H, Sakugawa H, Shokita H, Nakayoshi T, Kawakami Y, Kinjo F, Saito A, Shinjo M, Adaniya H, Mizushima T, Taira M. Prevalence and clinical features of hepatitis delta virus infection in the Miyako Islands, Okinawa, Japan. J Gastroenterol 1998; 33: 850-854","DOI":"10.1007\/s005350050186"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20482"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.05.021"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz001"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"Viana S, Paran\u00e1 R, Moreira RC, Compri AP, Macedo V. High prevalence of hepatitis B virus and hepatitis D virus in the western Brazilian Amazon. Am J Trop Med Hyg 2005; 73: 808-814","DOI":"10.4269\/ajtmh.2005.73.808"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(88)90166-6"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23653"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.07.005"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.06.008"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"Sagnelli E, Stroffolini T, Ascione A, Bonino F, Chiaramonte M, Colombo M, Craxi A, Giusti G, Manghisi OG, Pastore G. The epidemiology of hepatitis delta infection in Italy. Promoting Group. J Hepatol 1992; 15: 211-215","DOI":"10.1016\/0168-8278(92)90038-Q"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.02.011"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001163"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v25\/i32\/4580.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T15:27:49Z","timestamp":1610897269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v25\/i32\/4580.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":152,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2019,8,28]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v25.i32.4580","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,28]]}}}